Recent progress in development of antibiotics against Gram-negative bacteria

Yaoxue Xuebao

Volumn 48, Issue 7, 2013, Pages 993-1004

  Xu, Ze Qi ^a   Xu, Ze Yu ^b  

^a SynChem GMP   (United States)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Antibiotic; Gram negative bacteria; Multidrug resistant; New target and novel mechanism; Super bug

Indexed keywords

ANTIBIOTIC AGENT; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; ENZYME INHIBITOR; FERROUS ION; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDOMIMETIC AGENT; SIDEROMYCINS; TETRACYCLINE DERIVATIVE;

DRUG DEVELOPMENT; DRUG RESEARCH; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; ANIMAL; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; FERROUS COMPOUNDS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PEPTIDES; PEPTIDOMIMETICS; TETRACYCLINES;

EID: 84883621350     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Infectious Diseases Society of America. The 10 x ' 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 [J]. Clin Infect Dis, 2010, 50: 1081-1083.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America [J]. Clin Infect Dis, 2009, 48: 1-12.
3. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE [J]. J Infect Dis, 2008, 197: 1079-1081. (Pubitemid 351590040)
4. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge [J]. N Engl J Med, 2009, 360: 439-443.
5. Hvistendahl M. China takes aim at rampant antibiotic resistance [J]. Science, 2012, 336: 795.
6. Yezli S, Li H. Antibiotic resistance amongst healthcare-associated pathogens in China [J]. Int J Antimicrob Agents, 2012,40:389-397.
7. Taubes G. The bacteria fight back [J]. Science, 2008, 321:356-361.
8. Torres C. Up against wall [J]. Nat Med, 2010, 16: 628-631.
9. Silver LL. Challenges of antibacterial discovery [J]. Clin Microbiol Rev, 2011, 24: 71-109.
10. Coates A, Hu Y, Bax R, et al. The future challenges facing the development of new antimicrobial drugs [J]. Nat Rev Drug Discov, 2002, 1: 895-910. (Pubitemid 37361584)
11. Powers JH. Antimicrobial drug development - the past, the present, and the future [J]. Clin Microbiol Infect, 2004, 10 Suppl 4: 23-31.
12. Bartlett JG, Barie PS, Niederman MS, et al. Workshop on clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated pneumonia [J]. Clin Infect Dis, 2010, 51: S1-S3.
13. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use [J]. Curr Opin Investig Drugs, 2010, 11:182-191.
14. Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection [J]. Clin Infect Dis, 2012, 54: 568-574.
15. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin [J]. J Antimicrob Chemother, 2011, 66 Suppl 3: iii11-18.
16. Pan X, Wang P, Hu N, et al. A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans [J]. Drug Metab Pharmacokinet, 2011, 26: 387-398.
17. Chahine EB, Ferrill MJ, Poulakos MN. Doripenem: a new carbapenem antibiotic [J]. Am J Health Syst Pharm, 2010, 67: 2015-2024.
18. Giske CD, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli [J]. Antimicrob Agents Chemother, 2008, 52: 813-821. (Pubitemid 351358357)
19. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous Colistin versus intravenous Colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study [J]. Clin Infect Dis, 2010, 51: 1238-1244.
20. Velkov T, Thompson PE, Nation RL, et al. Structure-activity relationships of polymyxin antibiotics [J]. J Med Chem, 2010, 53: 1898-1916.
21. Coates ARM, Halls G, Hu Y. Novel classes of antibiotics or more of the same? [J]. Br J Pharmacol, 2011, 163: 184-194.
22. Dougherty TJ, Pucci MJ. Antibiotic Discovery and Development: Vol 1 and Vol 2 [M]. New York: Springer, 2012.
23. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria - time to react is now [J]. Drug Resist Updat, 2011, 14: 118-124.
24. Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae [J]. Curr Opin Microbiol, 2010, 13: 558-564.
25. Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future [J]. Antimicrob Agents Chemother, 2011, 55: 4943-4960.
26. Kuroki H, Tateno N, Ikeda H, et al. Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment [J]. J Infect Chemother, 2010, 16: 280-287.
27. Hirai Y, Takahata S, Yamada K, et al. Correlation of the antimicrobial activity of ME1036 with its binding af finities to the penicillin-binding proteins from Streptococcus pneumoniae strains [J]. J Antibiot, 2011, 64: 741-746.
28. Sader HS, Gales AC. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents [J]. Drugs, 2001, 61: 553-564. (Pubitemid 32453367)
29. Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms [J]. Antimicrob Agents Chemother, 2012, 56: 544-549.
30. Titelman E, Karlsson IM, Ge Y, et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae [J]. Diagn Microbiol Infect Dis, 2011, 70: 137-141.
31. Bebrone C, Lassaux P, Vercheval L, et al. Current challenges in antimicrobial chemotherapy. Focus on β-lactamase inhibition [J]. Drugs, 2010, 70: 651-679.
32. Ruzin A, Petersen PJ, Jones CH. Resistance development profiling of piperacillin in combination with the novel β-lactamase inhibitor BLI-489 [J]. J Antimicrob Chemother, 2010, 65: 252-257.
33. Jamieson CE, Lambert PA, Simpson IN. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms [J]. Antimicrob Agents Chemother, 2003, 47: 2615-2618. (Pubitemid 36919467)
34. Bowker KE, Noel AR, Walsh TR, et al. Pharmacodynamics of ceftazidime plus the serine β-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 β-lactamases [J]. Antimicrob Agents Chemother, 2004, 48:4482-4484. (Pubitemid 39434924)
35. Paukner S, Hesse L, Prezelj A, et al. In vitro activity of LK157, a novel tricyclic carbapenem as broad-spectrum β-lactamase inhibitor [J]. Antimicrob Agents Chemother, 2009, 53: 505-511.
36. Plantan I, Selic L, Mesar T, et al. 4-Substituted trinems as broad spectrum β-lactamase inhibitors: structure-based design, synthesis, and biological activity [J]. J Med Chem, 2007, 50:4113-4121. (Pubitemid 47301743)
37. Iglicar P, Legen I, Vilfan G, et al. Permeability of a novel β-lactamase inhibitor LK-157 and its ester prodrugs across rat jejunum in vitro [J]. J Pharm Pharmacol, 2009, 61: 1211-1218.
38. Ehmann DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor [J]. Proc Natl Acad Sci USA, 2012, 109: 11663-11668.
39. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-Mactams against Gram-negative bacteria, including OXA-48 β-Mactamase-producing Klebsiella pneumoniae [J]. Int J Antimicrob Agents, 2012, 39: 86-89.
40. Louie A, Castanheira M, Liu W, et al. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases [J]. Antimicrob Agents Chemother, 2012, 56:258-270.
41. Lagacé-Wiens PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C β-lactamases [J]. Antimicrob Agents Chemother, 2011, 55: 2434-2437.
42. Livermore DM, Mushtaq S, Barker K, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104) [J]. J Antimicrob Chemother, 2012, 67: 1354-1358.
43. Levasseur P, Girard AM, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates [J]. Antimicrob Agents Chemother, 2012, 56: 1606-1608.
44. Mangion IK, Ruck RT, Rivera N, et al. A concise synthesis of a β-lactamase inhibitor [J]. Org Lett, 2011, 13: 5480-5483.
45. Hirsch EB, Ledesma KR, Chang KT, et al. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria [J]. Antimicrob Agents Chemother, 2012, 56: 3753-3757.
46. Bhagunde P, Chang KT, Hirsch EB, et al. Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors [J]. Antimicrob Agents Chemother, 2012,56:2237-2240.
47. Ishii Y, Eto M, Mano Y, et al. In vitro potentiation of carbapenems with ME1071, a novel metallo-β-lactamase inhibitor, against metallo-β- lactamase-producing Pseudomonas aeruginosa clinical isolates [J]. Antimicrob Agents Chemother, 2010, 54: 3625-3629.
48. Livermore DM, Mushtaq S, Morinaka A, et al. Activity of carbapenems with ME1071 (disodium 2, 3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. With carbapenemases, including NDM enzymes [J]. J Antimicrob Chemother, 2013, 68: 153-158.
49. Yang L, Ye XS. Development of aminoglycoside antibiotics effective against resistant bacterial strains [J]. Curr Top Med Chem, 2010, 10: 1898-1926.
50. Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490 [J]. Curr Opin Microbiol, 2010, 13: 565-573.
51. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin [J]. Expert Rev Anti Infect Ther, 2012, 10: 459-473.
52. Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece [J]. J Chemother, 2012, 24: 191-194.
53. Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates [J]. J Antimicrob Chemother, 2011, 66: 48-53.
54. Xiao XY, Hunt DK, Zhou J, et al. Fluorocyclines. 1. 7-fluoro-9- pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent [J]. J Med Chem, 2012, 55: 597-605.
55. Grossman TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic [J]. Antimicrob Agents Chemother, 2012, 56: 2559-2564.
56. Hadley EB, Hancock REW. Strategies for the discovery and advancement of novel cationic antimicrobial peptides [J]. Curr Top Med Chem, 2010, 10: 1872-1881.
57. Findlay B, Zhanel GG, Schweizer F. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold [J]. Antimicrob Agents Chemother, 2010, 54: 4049-4058.
58. Wimley WC. Describing the mechanism of antimicrobial peptide action with the interfacial activity model [J]. ACS Chem Biol, 2010, 5: 905-917.
59. Baltzer SA, Brown MH. Antimicrobial peptides: promising alternatives to conventional antibiotics [J]. J Mol Microbiol Biotechnol, 2011, 20: 228-235.
60. Zhang Y, Zhao H, Yu GY, et al. Structure-function relationship of king cobra cathelicidin [J]. Peptides, 2010, 31: 1488-1493.
61. Li SA, Lee WH, Zhang Y. Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models [J]. Antimicrob Agents Chemother, 2012, 56: 3309-3317.
62. Melo MN, Dugourd D, Castanho MA. Omiganan penta-hydrochloride in the front line of clinical applications of antimicrobial peptides [J]. Recent Pat Antiinfect Drug Discov, 2006, 1: 201-207.
63. Rubinchik E, Dugourd D, Algaral T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models [J]. Int J Antimicrob Chemother, 2009, 34: 457-461.
64. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream [J]. Clin Infect Dis, 2008, 47: 1537-1545.
65. Gruenheid S, Le Moual H. Resistance to antimicrobial peptides in Gram-negative bacteria [J]. FEMS Microbiol Lett, 2012, 330: 81-89.
66. Fjell CD, Hiss JA, Hancock RE, et al. Designing antimicrobial peptides: form follows function [J]. Nat Rev Drug Discov, 2011, 11: 37-51.
67. Hu J, Chen C, Zhang S, et al. Designed antimicrobial and antitumor peptides with high selectivity [J]. Biomacro-molecules, 2011, 12: 3839-3843.
68. Tew GN, Scott RW, Klein ML, et al. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications [J]. Acc Chem Res, 2010, 43: 30-39.
69. Giuliani A, Rinaldi AC. Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches [J]. Cell Mol Life Sci, 2011, 68: 2255-2266.
70. Thaker HD, Sgolastra F, Clements D, et al. Synthetic mimics of antimicrobial peptides from triaryl scaffolds [J]. J Med Chem, 2011, 54: 2241-2254.
71. Yang L, Gordon VD, Mishra A, et al. Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes [J]. J Am Chem Soc, 2007, 129: 12141-12147. (Pubitemid 47556850)
72. Isaksson J, Brandsdal BO, Engqvist M, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption [J]. J Med Chem, 2011, 54: 5786-5795.
73. Saravolatz LD, Pawlak J, Johnson L, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus [J]. Antimicrob Agents Chemother, 2012, 56: 4478-4482.
74. Foley TL, Simeonov A. Targeting iron assimilation to develop new antibacterials [J]. Expert Opin Drug Discov, 2012, 7: 831-847.
75. Kelly RJ, Giaccone G. The role of talactoferrin β in the treatment of non-small cell lung cancer [J]. Expert Opin Biol Ther, 2010, 10: 1379-1386.
76. Venkatesh MP, Rong L. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis [J]. J Med Microbiol, 2008, 57(Pt 9): 1113-1121.
77. van der Does AM, Bogaards SJ, Ravensbergen B, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens [J]. Antimicrob Agents Chemother, 2010, 54: 811-816.
78. van der Does AM, Hensbergen PJ, Bogaards SJ, et al. The human lactoferrin-derived peptide hLF1-11 exerts immuno-modulatory effects by specific inhibition of myeloperoxidase activity [J]. J Immunol, 2012, 188: 5012-5019.
79. Velden WJ, van Iersel TM, Blijlevens NM, et al. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) [J]. BMC Med, 2009, 7: 44.
80. Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL197641 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms [J]. J Antimicrob Chemother, 2010, 65: 2382-2395.
81. Braun V, Pramanik A, Gwinner T, et al. Sideromycins: tools and antibiotics [J]. Biometals, 2009, 22: 3-13.
82. Ji C, Miller PA, Miller MJ. Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity [J]. J Am Chem Soc, 2012, 134: 9898-9901.
83. Ji C, Miller MJ. Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers [J]. Bioorg Med Chem, 2012, 20: 3828-3836.
84. Higgins PG, Stefanik D, Page MG, et al. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii [J]. J Antimicrob Chemother, 2012, 67: 1167-1169.
85. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli [J]. Antimicrob Agents Chemother, 2010, 54: 2291-2302.
86. Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters [J]. J Antimicrob Chemother, 2010, 65: 266-270.
87. Nikaido H, Pagès JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria [J]. FEMS Microbiol Rev, 2012, 36: 340-363.
88. Mima T, Schweizer HP, Xu ZQ. In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance [J]. J Antimicrob Chemother, 2011, 66: 73-78.
89. Schweizer HP. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery [J]. Expert Opin Drug Discov, 2012, 7: 633-642.
90. Yoshida K, Nakayama K, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate [J]. Bioorg Med Chem, 2007, 15: 7087-7097. (Pubitemid 47451787)
91. Schumacher A, Trittler R, Bohnert JA, et al. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes : role of enhanced efflux pump activity and inactivation [J]. J Antimicrob Chemother, 2007, 59: 1261-1264. (Pubitemid 47073344)
92. Coban AY, Guney AK, Tanriverdi Cayci Y, et al. Effect of 1-(1-naphtylmethyl)-piperazine, an efflux pump inhibitor, on antimicrobial drug susceptibilities of clinical Acinetobacter baumannii isolates [J]. Curr Microbiol, 2011, 62: 508-511.
93. Chevalier J, Mahamoud A, Baitiche M, et al. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains [J]. Int J Antimicrob Agents, 2010, 36: 164-168.
94. Mahamoud A, Chevalier J, Baitiche M, et al. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates [J]. Microbiology, 2011, 157: 566 -571.
95. Zeng B, Wang H, Zou L, et al. Evaluation and target validation of indole derivatives as inhibitors of the AcrAB-TolC efflux pump [J]. Biosci Biotechnol Biochem, 2010, 74: 2237-2241.
96. Oleksiewicz MB, Nagy Q Nagy E. Anti-bacterial monoclonal antibodies: back to the future? [J]. Arch Biochem Biophys, 2012, 526: 124-131.
97. ter Meulen J. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011 [J]. Infect Dis Clin North Am, 2011, 25: 789-802.
98. Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa Oil pneumonia [J]. J Antimicrob Chemother, 2011, 66:1110-1116.
99. François B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebocontrolled trial [J]. Crit Care Med, 2012, 40: 2320-2326.
100. Amara N, Krom BP, Kaufmann GF, et al. Macromolecular inhibition of quorum sensing: enzymes, antibodies, and beyond [J]. Chem Rev, 2011, 111: 195-208.
101. López EL, Contrini MM, Glatstein E, et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli [J]. Antimicrob Agents Chemother, 2010, 54:239-243.
102. Roux D, Pier GB, Skurnik D. Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes [J]. J Antimicrob Chemother, 2012, 67: 2785-2787.
103. Skurnik D, Davis MR Jr, Benedetti D, et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection [J]. J Infect Dis, 2012, 205: 1709-1718.
104. Seiradake E, Mao W, Hernandez V, et al. Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles [J]. J Mol Biol, 2009, 390: 196-207.
105. Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site [J]. Science, 2007, 316: 1759-1761. (Pubitemid 46988553)
106. Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011 [J]. J Antibiotics, 2011, 64: 413-425.